Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study
Open Access
- 1 August 2017
- journal article
- research article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 124 (2) , 311-317
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Aortic dose constraints when reirradiating thoracic tumorsRadiotherapy and Oncology, 2013
- The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancerRadiotherapy and Oncology, 2012
- Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake ValueJournal of Nuclear Medicine, 2012
- Consideration of Dose Limits for Organs at Risk of Thoracic Radiotherapy: Atlas for Lung, Proximal Bronchial Tree, Esophagus, Spinal Cord, Ribs, and Brachial PlexusInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Radiation Dose–Volume Effects in the LungInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scanRadiotherapy and Oncology, 2009
- Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105Journal of Clinical Oncology, 2008
- Errors and margins in radiotherapySeminars in Radiation Oncology, 2004